Tag: FR0010331421

Marseille, Jan. 05, 2021 (GLOBE NEWSWIRE) — IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format Selection of IPH6101/SAR443579 triggers a €7M milestone payment to Innate Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decision […]

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format Selection of IPH6101/SAR443579 triggers a €7M milestone payment to Innate MARSEILLE, France, Jan. 05, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the […]

MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences. ODDO BHF Digital ForumDate: January 7-11, 2021 SternIR Virtual Corporate Access EventDate: […]

MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences. ODDO BHF Digital ForumDate: January 7-11, 2021 SternIR Virtual Corporate Access EventDate: […]

Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.       ·ODDO BHF Digital ForumDate: January 7-11, 2021       ·SternIR Virtual Corporate Access EventDate: January […]

Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.       ·ODDO BHF Digital ForumDate: January 7-11, 2021       ·SternIR Virtual Corporate Access EventDate: January […]

Marseille, Dec. 11, 2020 (GLOBE NEWSWIRE) — Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio   Companies will develop a transition plan with the goal of returning full commercialization responsibilities to AstraZeneca in 2021  Companies will ensure availability of Lumoxiti to patients during transition […]

Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio  Companies will develop a transition plan with the goal of returning full commercialization responsibilities to AstraZeneca in 2021 Companies will ensure availability of Lumoxiti to patients during transition period Conference call to be held today […]

Phase 2 expansion cohort data supports ongoing Phase 3 trial Marseille, Dec. 03, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present additional data on its lead partnered asset, monalizumab, at the ESMO Immuno-oncology Virtual Congress being held from […]

Phase 2 expansion cohort data supports ongoing Phase 3 trial MARSEILLE, France, Dec. 03, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present additional data on its lead partnered asset, monalizumab, at the ESMO Immuno-oncology Virtual Congress being held […]